Stockscreener 앱 받기
0.6988
0.60%
-0.0042
전일 마감가:
$0.703
열려 있는:
$0.7199
하루 거래량:
18,532
Relative Volume:
0.01
시가총액:
$2.98M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-15.05%
1개월 성능:
-37.61%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.67
$0.72
1주일 범위
$0.67
$0.90
52주 변동 폭
$0.67
$4.80
Polyrizon Ltd Stock (PLRZ) Company Profile
PLRZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
0.70 | 2.98M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.11 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.60 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.04 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.24 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.35 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Polyrizon Ltd 주식(PLRZ)의 최신 뉴스
Polyrizon launches preclinical studies on intranasal version of treatment to reverse opioid overdoses - Marketscreener.com
Polyrizon advances naloxone intranasal delivery studies By Investing.com - Investing.com South Africa
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform - The Manila Times
Revolutionary Naloxone Delivery: Polyrizon Targets $2.4B Opioid Treatment Market - StockTitan
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 - The Manila Times
Polyrizon Releases Comprehensive 2024 Financial Report: Key Details Now Available - StockTitan
Polyrizon begins preclinical studies for nasal opioid overdose treatment By Investing.com - Investing.com Australia
Polyrizon Launches Preclinical Trials for Intranasal Naloxone - TipRanks
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform - The Manila Times
Polyrizon initiates preclinical studies for intranasal naloxone - TipRanks
Polyrizon Begins Preclinical Studies for Next-Gen Naloxone Delivery - StockTitan
Polyrizon appoints new board member Liron Carmel - MSN
Polyrizon Ltd. Announces Filing of Divisional Patent Application for Its Innovative Trap & Target (T&T) Intranasal Drug Delivery Platform - Marketscreener.com
Polyrizon files patent for nasal drug delivery tech - MSN
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform - Marketscreener.com
Game-Changing Nasal Drug Tech Could Transform Treatment of Seizures and Overdoses - StockTitan
Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ) - ACCESS Newswire
Polyrizon Ltd (NASDAQ: PLRZ) Declined -5.41%, What’s Next? Don’t Panic - Stocks Register
Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial - The Manila Times
Polyrizon Ltd. Commences GMP Manufacturing Preliminary Process for Its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial - Marketscreener.com
Polyrizon Advances PL-14 Allergy Blocker Manufacturing, Eyes $23B Nasal Spray Market - StockTitan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Polyrizon (PLRZ) Stock Climbs After Patent Publication Update - Stocks Telegraph
Polyrizon Shares Rise After Publication of National Patent Application - MarketWatch
Why Is Development-Stage Biotech Company Polyrizon Stock Surging Today? - Benzinga
Patents and new EV’s have these small caps perking - RagingBull
Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies - The Manila Times
Scisparc Ltd. Announces Initiation of Patient Recruitment for Its Clinical Trial with Sci-210 in Children with Autism Spectrum Disorder - Marketscreener.com
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
Scisparc Ltd. with Clearmind Medicine Inc. Publishes for the Innovative Combination of 3,4-Methylenedioxymethamphetamine with N-Acylethanolamines - Marketscreener.com
SciSparc Ltd. Announces Finalize an Exclusive Patent License Agreement with Polyrizon Ltd - Marketscreener.com
Clearmind Medicine Inc. Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Marketscreener.com
SciSparc Ltd. Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss - Marketscreener.com
Full Stock Market News from 2024-12-21 - StockTitan
SPRC stock touches 52-week low at $0.21 amid sharp decline - Investing.com India
Polyrizon's Retail Following Booms As Biotech Stock Triples On Manufacturing Deal For Allergy Blocker Trial - MSN
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs - The Manila Times
Polyrizon Strengthens Clinical Leadership Ahead of Key 2025 PL-14 Trial, Appoints Regulatory Expert - StockTitan
U.S. Stocks Drop Sharply with Losses Across Major Sectors, Amazon and American Express Lead Declines - mediahousepress
Beam Therapeutics (BEAM) Stock Dips Amid Biotech Sector Decline - GuruFocus.com
Lexicon Pharmaceuticals (LXRX) Stock Declines Amid Biotech Secto - GuruFocus.com
Allogene Therapeutics (ALLO) Stock Drops Amid Biotech Sector Dec - GuruFocus.com
Capricor Therapeutics (CAPR) Stock Dips Amid Biotech Sector Decl - GuruFocus.com
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 2.58% - Investing.com
United States shares lower at close of trade; Dow Jones Industrial Average down 2.58% - Investing.com India
Nektar Therapeutics (NKTR) Stock Plummets Amidst Biotech Sector Decline - GuruFocus.com
TFSA: 3 Top TSX Stocks for Your $7,000 Contribution - Yahoo Canada Finance
Wall Street-Heavily Traded - WDRB
Crude Oil Gains Over 1%, General Mills Shares Fall - Benzinga
Strategic DealSends Polyrizon (PLRZ) Shares To New Heights - Stocks Telegraph
Stellantis moves up launch of hybrid Ramcharger as EV demand cools - Yahoo Canada Finance
Polyrizon Ltd (PLRZ) 재무 분석
Polyrizon Ltd (PLRZ)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
5.68%
0.28%
자본화:
|
볼륨(24시간):